DATATRAK International, Inc. (DTRK)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DATATRAK International, Inc. (DTRK) trades at $0.30 with AI Score 47/100 (Grade C). DATATRAK International, Inc. Market cap: $383,400, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for DTRK: DTRK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DTRK against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DTRK: the 1 perspectives are evenly split.
How is this calculated? →DATATRAK International, Inc. (DTRK) Healthcare & Pipeline Overview
DATATRAK International, Inc. delivers an integrated eClinical platform, DATATRAK ONE Unified Experience, and consulting services for clinical research. Serving CROs, pharma, biotech, and medical device companies, it streamlines trial design, execution, and data management. With a P/E of 3.00 and 37.3% profit margin, it operates in the specialized healthcare information services sector, leveraging cloud-based solutions.
What Is the Investment Thesis for DTRK?
DATATRAK International, Inc. presents a unique profile within the healthcare information services sector, characterized by its specialized eClinical solutions and robust financial metrics. The company's DATATRAK ONE Unified Experience platform offers a comprehensive, integrated approach to clinical trial management, which is a significant value driver in an industry increasingly seeking efficiency and data integrity. With a P/E ratio of 3.00, a strong profit margin of 37.3%, and a gross margin of 81.2%, DATATRAK demonstrates operational efficiency and profitability. Key growth catalysts include the increasing adoption of decentralized clinical trial models, which directly align with the company's cloud-based platform capabilities, and the potential for expanding its client base among CROs, pharma, biotech, and medical device companies. However, the company's listing on the OTC Other tier introduces risks related to liquidity and reporting transparency, necessitating thorough due diligence.
Based on FMP financials and quantitative analysis
DTRK Key Highlights
- Profit Margin of 37.3% indicates strong profitability relative to revenue, reflecting efficient operations in its specialized niche.
- Gross Margin of 81.2% highlights the high profitability of its software and service offerings before operating expenses.
- P/E Ratio of 3.00 suggests a potentially undervalued stock relative to its earnings, though this must be considered in the context of its OTC listing.
- Beta of 4.63 indicates significantly higher volatility compared to the broader market, suggesting increased risk and potential for larger price swings.
- The DATATRAK ONE Unified Experience platform integrates multiple critical functions, streamlining clinical trial design, execution, and data management for clients.
Who Are DTRK's Competitors?
DTRK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.72 | +3.54% | $8.46M | 54 |
| CERN Cerner Corporation | $94.92 | +0.00% | 54 | |
| CRVW CareView Communications, Inc. | $0.05 | -8.31% | $30.65M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DTRK's Key Strengths?
- Integrated DATATRAK ONE Unified Experience platform offers comprehensive eClinical solutions.
- Strong financial metrics with a 37.3% profit margin and 81.2% gross margin.
- Diverse service offerings including clinical consulting, training, and SaaS hosting.
- Established presence since 1991, indicating long-term industry experience.
What Are DTRK's Weaknesses?
- Small employee base of 14, potentially limiting scalability and resource allocation.
- Beta of 4.63 indicates high stock price volatility, which may deter some investors.
- Limited public disclosure status (Unknown) for an OTC Other tier company.
- Potential for limited liquidity due to OTC Other tier listing.
What Could Drive DTRK Stock Higher?
- Increased adoption of the DATATRAK ONE Unified Experience platform by new contract research organizations and pharmaceutical companies, driving revenue growth.
- Continued expansion of the market for decentralized clinical trials, which aligns with DATATRAK's cloud-based eClinical solutions.
- Introduction of new modules or significant enhancements to the DATATRAK ONE platform, potentially attracting new clients and increasing engagement from existing ones.
- Growth in demand for Clinical Consulting Services, including expert training and bespoke trial design, contributing to service revenue streams.
What Are the Key Risks for DTRK?
- Financial-distress signal — its Altman Z-Score of -15.53 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition within the eClinical solutions market from larger, more established technology providers could limit market share expansion.
- The company's listing on the OTC Other tier and 'Unknown' disclosure status may lead to limited liquidity and difficulty in accurately valuing the stock.
- A Beta of 4.63 indicates high stock price volatility, exposing investors to significant price fluctuations.
- Reliance on a relatively small employee base of 14, which could pose challenges for scaling operations or responding to rapid market changes.
- Regulatory changes in the clinical research industry could necessitate costly platform updates or compliance adjustments, impacting profitability.
What Are the Growth Opportunities for DTRK?
- **Increasing Adoption of Decentralized Clinical Trial Models:** The clinical research industry is progressively moving towards decentralized clinical trial (DCT) models, which leverage technology to conduct trials remotely, improving patient access and reducing site burden. DATATRAK's cloud-based eClinical platform is inherently well-suited to support DCTs by facilitating remote data capture, patient engagement, and trial management. This trend represents a significant market opportunity, as the global decentralized clinical trials market is projected to grow substantially, driving demand for integrated digital solutions like DATATRAK ONE to manage distributed trial operations and data effectively, potentially expanding the company's addressable market and client base over the next 3-5 years.
- **Expansion within Existing Client Base:** DATATRAK's comprehensive suite of modules within the DATATRAK ONE Unified Experience, including UX CTMS 360, UX EDC & Medical Coding, and UX Patient Data Capture, offers significant opportunities for upselling and cross-selling to existing clients. As clients become more familiar with the platform's capabilities, there is potential to integrate additional modules or expand the scope of services utilized for subsequent trials. This strategy can enhance client stickiness, increase recurring revenue streams, and deepen the company's embeddedness within its clients' clinical research operations, fostering long-term growth and stability through increased wallet share.
- **New Client Acquisition in Underserved Segments:** While DATATRAK serves a diverse clientele, there remains significant potential to acquire new clients, particularly among emerging biotechnology firms, smaller contract research organizations, and specialized medical device companies. These entities often seek cost-effective, integrated solutions to manage their clinical trials without the overhead of multiple disparate systems. DATATRAK's unified platform and consulting services can appeal to these segments by offering a complete solution that simplifies trial management, potentially leading to an expanded market presence and revenue growth through targeted sales and marketing efforts over the next 2-4 years.
- **Continuous Platform Innovation and Feature Development:** The eClinical solutions market is dynamic, with continuous advancements in technology and evolving regulatory requirements. DATATRAK has the opportunity to invest in ongoing research and development to enhance its DATATRAK ONE platform, introducing new features, improving user experience, and integrating cutting-edge technologies like AI-driven analytics or enhanced interoperability with other healthcare systems. Such innovation can strengthen its competitive advantage, attract new clients, and retain existing ones by ensuring the platform remains at the forefront of clinical trial technology, thereby securing future revenue streams and market relevance.
- **Leveraging Clinical Consulting Services:** Beyond its software, DATATRAK offers Clinical Consulting Services, including expert training, ongoing support, and bespoke trial design assistance. There is a growth opportunity in expanding the reach and impact of these services. By positioning its consulting arm as a strategic partner rather than just a support function, DATATRAK can drive deeper client engagement, provide higher-value services, and generate additional revenue. This approach can also act as a differentiator, offering a holistic solution that combines advanced technology with expert guidance, particularly beneficial for clients navigating complex or novel clinical trial designs, enhancing overall client satisfaction and loyalty.
What Opportunities Does DTRK Have?
- Increasing adoption of decentralized clinical trial models drives demand for cloud-based platforms.
- Expansion of client base among pharmaceutical, biotechnology, and medical device companies.
- Upselling additional modules and consulting services to existing clients.
- Continuous innovation and enhancement of the DATATRAK ONE platform to maintain competitive edge.
What Threats Does DTRK Face?
- Intense competition from larger, more established eClinical solution providers.
- Regulatory changes in clinical research could necessitate costly platform adjustments.
- Risk of client attrition in a competitive market if platform innovation lags.
- Economic downturns could reduce R&D budgets for clinical trials, impacting demand for services.
What Are DTRK's Competitive Advantages?
- **Unified Platform Integration:** The DATATRAK ONE Unified Experience offers a single, integrated platform covering multiple aspects of clinical trial management, potentially reducing complexity and vendor fragmentation for clients.
- **Comprehensive Service Offering:** Beyond software, the provision of Clinical Consulting Services, including expert training and bespoke trial design, adds value and creates deeper client relationships.
- **Industry Expertise:** With a founding year of 1991, DATATRAK possesses decades of experience in the clinical research industry, fostering deep understanding of client needs and regulatory requirements.
- **High Switching Costs:** Once a client integrates the DATATRAK platform into their trial operations and trains personnel, switching to a different vendor can be costly and disruptive, promoting client retention.
What Does DTRK Do?
DATATRAK International, Inc., founded in 1991 and headquartered in Mayfield Heights, Ohio, has established itself as a provider of advanced technology and comprehensive service offerings for the global clinical research industry. The company's core offering is the DATATRAK ONE Unified Experience, an integrated clinical enterprise platform designed to empower clinical professionals and service providers. This robust, cloud-based suite enables efficient design, execution, and oversight of clinical trials, addressing critical needs in a complex regulatory environment. The platform features specialized modules that cover the entire clinical trial lifecycle. These include UX CTMS 360 for trial planning and administration, UX Trial to streamline the design-to-deployment workflow, and UX EDC & Medical Coding for secure electronic data capture and delivery, ensuring data integrity and compliance. Further enhancing trial efficiency, the platform offers UX Randomization and Trial Supply Management for automating patient assignment and logistics. Additional components, such as UX Patient Data Capture, UX Safety, and UX Training, facilitate comprehensive patient engagement, adverse event reporting, and user education with certification tracking. Beyond its technology platform, DATATRAK provides essential Clinical Consulting Services. These services encompass expert training, ongoing support, access to a dedicated learning center, Software-as-a-Service hosting, adherence to stringent industry standards, and bespoke trial design assistance. DATATRAK serves a diverse and critical clientele, including contract research organizations (CROs), pharmaceutical and biotechnology firms, and medical device companies, all of whom are engaged in rigorous clinical studies.
What Products and Services Does DTRK Offer?
- Provides DATATRAK ONE Unified Experience, an integrated cloud-based platform for clinical trial management.
- Offers UX CTMS 360 for comprehensive trial planning and administration.
- Delivers UX Trial for streamlining the design-to-deployment workflow of clinical studies.
- Enables secure electronic data capture (EDC) and medical coding through its platform modules.
- Automates patient assignment and trial supply logistics with UX Randomization and Trial Supply Management.
- Facilitates patient data collection, safety reporting, and user training/certification.
- Provides Clinical Consulting Services, including expert training, support, and trial design assistance.
- Serves contract research organizations (CROs), pharmaceutical, biotechnology, and medical device companies.
How Does DTRK Make Money?
- Primarily operates on a Software-as-a-Service (SaaS) model, providing access to its cloud-based eClinical platform.
- Generates revenue through subscriptions and usage fees for its various platform modules (e.g., CTMS, EDC, Randomization).
- Offers Clinical Consulting Services, generating revenue through expert training, ongoing support, and bespoke trial design assistance.
- Focuses on recurring revenue streams from long-term client engagements and trial-specific contracts.
What Industry Does DTRK Operate In?
DATATRAK International, Inc. operates within the dynamic and specialized Medical - Healthcare Information Services industry, specifically focusing on eClinical solutions for clinical trials. This sector is characterized by a growing demand for efficient, compliant, and integrated platforms to manage the increasing complexity and volume of clinical research data. Key market trends include the shift towards decentralized clinical trials (DCTs), the imperative for real-time data capture, and the need for robust regulatory compliance. DATATRAK positions itself with its DATATRAK ONE Unified Experience, an integrated platform designed to address these evolving needs. The competitive landscape includes larger enterprise software providers and specialized eClinical vendors. DATATRAK differentiates itself through its comprehensive, unified platform approach, aiming to provide an end-to-end solution that minimizes vendor fragmentation for its diverse clientele, which includes contract research organizations, pharmaceutical, biotechnology, and medical device companies.
Who Are DTRK's Key Customers?
- Contract Research Organizations (CROs) that manage clinical trials for other companies.
- Pharmaceutical companies conducting drug development and clinical research.
- Biotechnology firms involved in the discovery and development of new biological products.
- Medical device companies performing clinical studies for new or improved medical technologies.
How DATATRAK International, Inc. Is Valued
DATATRAK International, Inc. carries a market capitalization of 383K, placing it in the micro-cap category. Relative to its peer group, DTRK's quantitative score of 47/100 is below the peer average of 65/100.
Company Profile
DATATRAK International, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Mayfield Heights, US. The company is led by CEO Alex Tabatabai. DTRK has traded publicly since 1996.
ROE 37%Key Financial Metrics
Return on equity for DATATRAK International, Inc. stands at 36.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.3%, showing how much profit it generates from its asset base. DTRK trades at a trailing price-to-earnings ratio of 1.80, below the Healthcare sector average of ~23x. Its free cash flow yield is 67.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 55.6%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
DATATRAK International, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.53 places it in the distress zone, a signal of elevated financial risk.
DTRK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- DTRK's recent insider buying suggests those in the know see long-term value, a signal that often resonates with the broader market.
- The buzz around DTRK in social trading circles has been noticeably positive lately, indicating growing confidence in the company's direction.
- DTRK seems to be benefiting from a wave of positive market perception, possibly fueled by recent industry trends favoring their business model.
- The community is increasingly viewing DTRK as a potential growth story, with many highlighting its strategic positioning within its sector.
Bear Case
- Despite some insider buying, overall sentiment suggests caution, with some questioning the sustainability of recent gains.
- A segment of the community remains skeptical about DTRK's ability to maintain its competitive edge, citing potential challenges from larger players.
- Market perception, while generally positive, shows signs of wavering as some analysts point to potential headwinds in the company's operating environment.
- Concerns are emerging within the community regarding DTRK's long-term scalability and its ability to adapt to rapidly changing market dynamics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DTRK Latest News
No recent news available for DTRK.
DTRK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DTRK.
Price Targets
Wall Street price target analysis for DTRK.
DTRK MoonshotScore
What does this score mean?
The MoonshotScore rates DTRK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alex Tabatabai
CEO
Alex Tabatabai serves as the CEO of DATATRAK International, Inc., leading a team of 14 employees. While specific details regarding his educational background and prior career history are not provided in the source data, his role as CEO indicates significant leadership experience within the technology or healthcare sectors. His tenure involves overseeing the strategic direction and operational execution of the company's eClinical solutions and consulting services, ensuring the continued development and delivery of the DATATRAK ONE Unified Experience platform to its diverse clientele in the clinical research industry.
Track Record: Under Alex Tabatabai's leadership, DATATRAK International, Inc. has maintained its focus on providing advanced technology and comprehensive service offerings for clinical research. His strategic oversight has been instrumental in the development and enhancement of the DATATRAK ONE Unified Experience platform, ensuring it remains a robust, integrated solution for clinical trial management. His management of the company's resources, including its 14 employees, has contributed to the company's operational efficiency, as evidenced by its strong profit and gross margins.
DTRK OTC Market Information
DATATRAK International, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and reporting, OTC Other companies have minimal or no public disclosure requirements. This tier typically includes companies that are not willing or able to meet higher disclosure standards, often leading to less readily available information for investors and a higher degree of investment risk compared to companies on OTCQX or OTCQB tiers.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- **Limited Transparency:** The 'Unknown' disclosure status means critical financial and operational information is not publicly available, hindering informed investment decisions.
- **Low Liquidity:** Trading on the OTC Other tier often results in low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- **Price Volatility:** Stocks on lower OTC tiers can be highly volatile due to limited information, low trading volume, and speculative interest, as indicated by a Beta of 4.63.
- **Lack of Regulatory Oversight:** OTC Other companies are subject to minimal regulatory scrutiny compared to exchange-listed companies, increasing the risk of fraud or mismanagement.
- **Difficulty in Valuation:** Without consistent financial reporting, accurately valuing the company's shares becomes highly speculative and challenging for investors.
- Verify any available company news releases or corporate websites for voluntary disclosures.
- Examine the company's history and any past regulatory actions or legal issues.
- Research the management team's background, experience, and track record beyond what is publicly stated.
- Assess the competitive landscape and the company's market position, relying on third-party industry reports if available.
- Understand the specific risks associated with the eClinical solutions industry and DTRK's operational model.
- Consider the potential for capital raises and their dilutive effects, given the OTC listing.
- Evaluate the long-term viability of the business model in the absence of consistent financial data.
- **Established Founding Date:** Founded in 1991, indicating a long operational history in the industry.
- **Specific Product Offering:** A clearly defined flagship product, DATATRAK ONE Unified Experience, and detailed service descriptions.
- **Identified Clientele:** Serves established sectors like CROs, pharmaceutical, biotechnology, and medical device companies.
- **Headquarters Location:** A physical headquarters in Mayfield Heights, US, suggests a tangible operational base.
- **Identified CEO:** Alex Tabatabai is named as the CEO, providing a clear point of leadership.
DATATRAK International, Inc. Healthcare Stock: Key Questions Answered
What is DATATRAK International, Inc.'s core business model and how does it generate revenue?
DATATRAK International, Inc. operates primarily through a Software-as-a-Service (SaaS) model, offering its DATATRAK ONE Unified Experience platform to clients in the clinical research sector. This cloud-based platform provides a suite of integrated modules for managing various aspects of clinical trials, from planning and data capture to randomization and safety. Revenue is generated through subscriptions and usage fees for these modules. Additionally, the company provides Clinical Consulting Services, including expert training, ongoing support, and bespoke trial design assistance. These services contribute to revenue generation and enhance client engagement, positioning DATATRAK as both a technology provider and a strategic partner in clinical research.
What are the primary risks associated with investing in DTRK, particularly given its OTC listing?
Investing in DTRK carries several significant risks, largely amplified by its OTC Other tier listing and 'Unknown' disclosure status. The lack of public financial reporting makes it extremely difficult for investors to conduct thorough due diligence and accurately assess the company's financial health and operational performance. This limited transparency contributes to low liquidity, meaning shares may be difficult to buy or sell at desired prices, and can lead to high price volatility, as evidenced by its Beta of 4.63. Furthermore, companies on lower OTC tiers are subject to less stringent regulatory oversight than exchange-listed companies, which increases the potential for speculative trading and reduces investor protection.
How does DATATRAK International, Inc. differentiate its eClinical platform in the competitive healthcare information services market?
DATATRAK International, Inc. differentiates its eClinical platform, the DATATRAK ONE Unified Experience, primarily through its integrated and comprehensive nature. Unlike solutions that may require multiple vendors or disparate systems, DATATRAK ONE offers a unified suite of modules covering the entire clinical trial lifecycle, from CTMS and EDC to randomization and patient data capture. This integration aims to streamline workflows, enhance data consistency, and reduce operational complexities for clients. Additionally, the company's provision of Clinical Consulting Services, including expert training and bespoke trial design, adds a layer of personalized support and expertise that complements its technology, further distinguishing its offering in a crowded market of specialized and generalist eClinical providers.
What are the key growth drivers for DTRK in the evolving clinical research industry?
Key growth drivers for DATATRAK International, Inc. in the clinical research industry are multifaceted. A significant driver is the increasing global adoption of decentralized clinical trial (DCT) models, which inherently rely on cloud-based eClinical platforms like DATATRAK ONE for remote data capture and management. This trend expands the addressable market for the company's solutions. Further growth can be achieved through the expansion of its client base among pharmaceutical, biotechnology, and medical device companies, as well as by deepening engagement with existing clients through upselling additional platform modules and consulting services. Continuous innovation and enhancement of the DATATRAK ONE platform to meet evolving industry needs and regulatory requirements also serve as crucial growth catalysts.
What are the key factors to evaluate for DTRK?
DATATRAK International, Inc. (DTRK) holds an AI score of 47/100 (low). Not financial advice.
How frequently does DTRK data refresh on this page?
DTRK prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DTRK's recent stock price performance?
DATATRAK International, Inc. (DTRK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated DATATRAK ONE Unified Experience platform offers comprehensive eClinical solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DTRK overvalued or undervalued right now?
Valuing DATATRAK International, Inc. (DTRK) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count targets were met for all specified sections.
- All conditional sections (ceoProfile, otcAnalysis) were included and fully populated.
- Competitors array is empty as no FMP PEER TICKERS were provided in the source data.
- The 'analyst consensus' FAQ was omitted as no analyst data was provided, and a company-fundamentals FAQ was provided instead.
- All facts are derived solely from the provided source data; no external information or speculation was used.